Chemotherapeutics: Kinase Inhibitors and Monoclonal Antibodies Flashcards

1
Q

-tinib suffix for

A

tyrosine kinase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Gefitinib MOA

A

inhibits tyrosine kinase domain of EGFR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Gefitinib treats

A

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

gefitnib side effects

A

skin rash;acne syndome, diarrhea, anorexia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

gefitinib cautions

A

metabolized by CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CYP3A4 inhibited by

A

grapefruit juice and warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

gefitinib unique properties

A

monotherapy and related drug erlotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

imatinib MOA

A

inhibits BCR-Abl kinase (tyrosine kinase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

imatinib treats

A

CML and GI stormal tumors (GIST)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

imatinib side effects

A

fluid retention/CHF, n/v/d, prolong QT interval, hepatotoxicity, liver metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

lapatinib MOA

A

blocks tyrosine kinase actives of EGFR and HER2/neu

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

lapatinib treats

A

breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

lapatinib side effects

A

n/d, rash, can prolong QT interval, dehydration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

sunitinib MOA

A

inhibits VEGFRalpha, beta, 1,2,3 and c-kit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

sunitinib treats

A

kidney and pancreatic cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sunitinib side effects

A

diarrhea, HTN, bleeding complications, CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

sorafenib MOA

A

inhibits VEGFR2,3, PDGFR and Raf kinases

18
Q

sorafenib treats

A

kidney and liver cancers

19
Q

sorafenib side effects

A

rash & skin problems/hand-foot syndrom, HTN, bleeding complications, CYP3A4

20
Q

-xi

A

chimeric

21
Q

-mab

A

monoclonal antibody

22
Q

all Mabs can cause what kind of reaction

A

infusion reaction

23
Q

Bevacizumab MOA

A

binds and blocks VEGF-A; prevents new angiogenesis

24
Q

Bevacizumab treats

A

metastatic colorectal cancer

25
Q

bevacizumab side effects

A

HTN, Arterial thombotic events, diarrhea, stomatitis, GI perforations

26
Q

Cetuximab MOA

A

binds and inhibits EGFR signaling

27
Q

cetuximab treats

A

colorectal cancer

28
Q

cetuximab side effects

A

dyspnea, hypotension, interstitial lung dz, rash

29
Q

cetuximab rash indicative of

A

positive response to therapy

30
Q

rituximab MOA

A

antiCD20 mab, depletes B lymphocytes (attached by CD8)

31
Q

rituximab treats

A

leukemias/lymphomas (NHL and CLL)

32
Q

rituximab side effects

A

infusion reactions (some fatal), HTN, Brochospasm, angioedema, arrythimias, tumorlysis syndome can lead to kidney failure

33
Q

trastuzumab MOA

A

Blnds/blocks HER2

34
Q

trastuzumab treats

A

metastatic breast cancer

35
Q

trastuzumab side effects

A

CHF, cardiomyopathy, flu-like symptoms, n/v

36
Q

Denosumab MOA

A

targets RANK Ligand in osteoclasts, blocks bone resorption, prevents fractures

37
Q

denosumab treats

A

prostate and breast cancers

38
Q

denosumab side effects

A

osteonecrosis of the jaw and dermatological reactions

39
Q

denosumab needs to be taken with

A

calcium and vit D

40
Q

Pembrolizumab MOA

A

blocks PD1 (checkpoint inhibitor)